KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Short term Debt (2018 - 2021)

Twist Bioscience (TWST) has disclosed Short term Debt for 4 consecutive years, with $9.1 million as the latest value for Q4 2021.

  • On a quarterly basis, Short term Debt rose 172.49% to $9.1 million in Q4 2021 year-over-year; TTM through Dec 2021 was $9.1 million, a 172.49% increase, with the full-year FY2021 number at $1.6 million, down 53.44% from a year prior.
  • Short term Debt was $9.1 million for Q4 2021 at Twist Bioscience, up from $1.6 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $9.1 million in Q4 2021 to a low of $1.6 million in Q3 2021.
  • A 4-year average of $3.5 million and a median of $3.3 million in 2018 define the central range for Short term Debt.
  • Biggest YoY gain for Short term Debt was 172.49% in 2021; the steepest drop was 53.44% in 2021.
  • Twist Bioscience's Short term Debt stood at $3.3 million in 2018, then changed by 0.0% to $3.3 million in 2019, then changed by 0.0% to $3.3 million in 2020, then surged by 172.49% to $9.1 million in 2021.
  • Per Business Quant, the three most recent readings for TWST's Short term Debt are $9.1 million (Q4 2021), $1.6 million (Q3 2021), and $2.4 million (Q2 2021).